## Janice E Graham

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5423608/publications.pdf

Version: 2024-02-01

279798 155660 3,232 80 23 55 citations g-index h-index papers 83 83 83 3637 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Stigma and blame related to COVID-19 pandemic: A case-study of editorial cartoons in Canada. Social Science and Medicine, 2022, 296, 114803.	3.8	21
2	Prebunking messaging to inoculate against COVID-19 vaccine misinformation: an effective strategy for public health. Journal of Communication in Healthcare, 2022, 15, 232-242.	1.5	15
3	The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good. BMJ Global Health, 2022, 7, e008684.	4.7	122
4	Deferring Risk: Limitations to the Evidence in Product Labels for Vaccine Use in Pregnancy. Journal of Women's Health, 2022, 31, 1103-1112.	3.3	2
5	" <i>I don't think there's a point for me to discuss it with my patientsâ€</i> : exploring health care providers' views and behaviours regarding COVID-19 vaccination. Human Vaccines and Immunotherapeutics, 2022, 18, .	3.3	1
6	Royal society of Canada COVID-19 report: Enhancing COVID-19 vaccine acceptance in Canada. Facets, 2021, 6, 1184-1246.	2.4	25
7	COVID-19 vaccine safety questions and answers for healthcare providers (CONSIDER). Vaccine, 2021, 39, 2504-2505.	3.8	1
8	Under consent: participation of people with HIV in an Ebola vaccine trial in Canada. BMC Medical Ethics, 2021, 22, 42.	2.4	4
9	Healthcare providers' interpretations of product labelling information developed through a consensus stakeholder approach. Vaccine, 2021, 39, 2652-2659.	3.8	4
10	Ethics check-up of public health immunization programs in Canada. Canada Communicable Disease Report, 2021, 47, 237-241.	1.3	0
11	From sandbox to pandemic: Agile reform of Canadian drug regulation. Health Policy, 2021, 125, 1115-1120.	3.0	9
12	Regulators, Pivotal Clinical Trials, and Drug Regulation in the Age of COVID-19. International Journal of Health Services, 2021, 51, 5-13.	2.5	11
13	Strengthening vaccination frameworks: Findings of a study on the legal foundations of National Immunization Technical Advisory Groups (NITAGs). Vaccine, 2020, 38, 840-846.	3.8	0
14	Governing off-label vaccine use: An environmental scan of the Global National Immunization Technical Advisory Group Network. Vaccine, 2020, 38, 1089-1095.	3.8	5
15	A public health timeline to prepare for COVID-19 vaccines in Canada. Canadian Journal of Public Health, 2020, 111, 945-952.	2.3	11
16	Immunization governance: Mandatory immunization in 28 Global NITAG Network countries. Vaccine, 2020, 38, 7258-7267.	3.8	9
17	Vaccination discourses among chiropractors, naturopaths and homeopaths: A qualitative content analysis of academic literature and Canadian organizational webpages. PLoS ONE, 2020, 15, e0236691.	2.5	6
18	Perinatal health care providers' approaches to recommending and providing pertussis vaccination in pregnancy: a qualitative study. CMAJ Open, 2020, 8, E377-E382.	2.4	15

#	Article	IF	Citations
19	From discovery to delivery: public sector development of the <i>r</i> VSV-ZEBOV Ebola vaccine. Journal of Law and the Biosciences, 2020, 7, lsz019.	1.6	25
20	Transparency too little, too late? Why and how Health Canada should make clinical data and regulatory decision-making open to scrutiny in the face of COVID-19. Journal of Law and the Biosciences, 2020, 7, Isaa083.	1.6	5
21	Title is missing!. , 2020, 15, e0236691.		o
22	Title is missing!. , 2020, 15, e0236691.		0
23	Title is missing!. , 2020, 15, e0236691.		0
24	Title is missing!. , 2020, 15, e0236691.		0
25	Ebola vaccine innovation: a case study of pseudoscapes in global health. Critical Public Health, 2019, 29, 401-412.	2.4	11
26	How Do Postgenomic Innovations Emerge? Building Legitimacy by Proteomics Standards and Informing the Next-Generation Technology Policy. OMICS A Journal of Integrative Biology, 2019, 23, 406-415.	2.0	0
27	Developing product label information to support evidence-informed use of vaccines in pregnancy. Vaccine, 2019, 37, 7138-7146.	3.8	9
28	Is physician dismissal of vaccine refusers an acceptable practice in Canada? A 2018 overview. Paediatrics and Child Health, 2019, 24, 92-97.	0.6	6
29	Technologies of trust in epidemic response: openness, reflexivity and accountability during the 2014–2016 Ebola outbreak in West Africa. BMJ Global Health, 2019, 4, e001272.	4.7	38
30	North End Community Health Centre in Halifax, NS: Relationship-based care goes beyond collaborative care to address patient needs. Canadian Family Physician, 2019, 65, e344-e355.	0.4	0
31	Prepared for the â€unexpected'? Lessons from the 2014â€"2016 Ebola epidemic in West Africa on integrating emergent theory designs into outbreak response. BMJ Global Health, 2018, 3, e000990.	4.7	14
32	Lueurs et leurres de la santé globale. Anthropologie & Développement, 2017, , 213-234.	0.0	0
33	Ambiguous Capture: Collaborative Capitalism and the Meningitis Vaccine Project. Medical Anthropology: Cross Cultural Studies in Health and Illness, 2016, 35, 419-432.	1.2	14
34	Just Evidence: Opening Health Knowledge to a Parliament of Evidence., 2016,, 325-350.		0
35	Knowledge Translation: Moving Proteomics Science to Innovation in Society. OMICS A Journal of Integrative Biology, 2016, 20, 352-361.	2.0	3
36	Exploring the post-genomic world: differing explanatory and manipulatory functions of post-genomic sciences. New Genetics and Society, 2016, 35, 49-68.	1,2	11

#	Article	IF	Citations
37	Understanding Vaccine Hesitancy in Canada: Results of a Consultation Study by the Canadian Immunization Research Network. PLoS ONE, 2016, 11, e0156118.	2.5	121
38	Regulating prescription drugs for patient safety: Does Bill C-17 go far enough?. Cmaj, 2014, 186, E287-E292.	2.0	9
39	Substitute consent practices in the face of uncertainty: a survey of Canadian researchers in aging. International Psychogeriatrics, 2013, 25, 1821-1830.	1.0	6
40	Faster Access to New Drugs: Fault Lines Between Health Canada's Regulatory Intent and Industry Innovation Practices. Ethics in Biology, Engineering & Medicine, 2013, 4, 231-239.	0.1	4
41	Risk, choice and the â€~girl vaccine': Unpacking human papillomavirus (HPV) immunisation. Health, Risk and Society, 2012, 14, 57-69.	1.7	31
42	Capacity for a global vaccine safety system: The perspective of national regulatory authorities. Vaccine, 2012, 30, 4953-4959.	3.8	37
43	Challenges to immunization: the experiences of homeless youth. BMC Public Health, 2012, 12, 338.	2.9	15
44	Are Canadians Providing Advance Directives about Health Care and Research Participation in the Event of Decisional Incapacity?. Canadian Journal of Psychiatry, 2011, 56, 209-218.	1.9	19
45	Is consent for research genuinely informed? Using decision aid tools to obtain informed consent in the global south. Journal of Global Ethics, 2011, 7, 349-359.	0.5	9
46	Comfort with proxy consent to research involving decisionally impaired older adults: do type of proxy and risk-benefit profile matter?. International Psychogeriatrics, 2011, 23, 1479-1488.	1.0	12
47	Global challenges of implementing human papillomavirus vaccines. International Journal for Equity in Health, 2011, 10, 27.	3.5	48
48	Standardization and Omics Science: Technical and Social Dimensions Are Inseparable and Demand Symmetrical Study. OMICS A Journal of Integrative Biology, 2010, 14, 327-332.	2.0	24
49	Assessment of factors associated with complete immunization coverage in children aged 12-23 months: a cross-sectional study in Nouna district, Burkina Faso. BMC International Health and Human Rights, 2009, 9, S10.	2.5	86
50	Genetically Modified Organisms as Public Goods: Plant Biotechnology Transfer in Colombia. Culture and Agriculture, 2009, 31, 26-38.	0.2	3
51	Multiple institutional rationalities in the regulation of health technologies: an ethnographic examination. Science and Public Policy, 2009, 36, 445-455.	2.4	8
52	Facilitating Regulation: The Dance of Statistical Significance and Clinical Meaningfulness in Standardizing Technologies for Dementia. BioSocieties, 2008, 3, 241-263.	1.3	12
53	Race as a variable in pharmacogenomics science: from empirical ethics to publication standards. Pharmacogenetics and Genomics, 2008, 18, 837-841.	1.5	6
54	Memorabilities: enduring relationships, memories and abilities in dementia. Ageing and Society, 2007, 27, 533-554.	1.7	27

#	Article	IF	Citations
55	Asymmetry in Scientific Method and Limits to Cross-Disciplinary Dialogue. Journal of Investigative Medicine, 2007, 55, 130-141.	1.6	6
56	The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial. BMC Neurology, 2007, 7, 26.	1.8	90
57	Mild Cognitive Impairment: Ethical Considerations for Nosological Flexibility in Human Kinds. Philosophy, Psychiatry and Psychology, 2006, 13, 31-43.	0.4	26
58	Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opinion on Pharmacotherapy, 2006, 7, 119-133.	1.8	28
59	Reciprocal relations: The recognition and co-construction of caring with Alzheimer's disease. Journal of Aging Studies, 2006, 20, 335-349.	1.4	43
60	Anthropological contributions to the understanding of age-related cognitive impairment. Lancet Neurology, The, 2005, 4, 320-326.	10.2	33
61	Smart Regulation: Will the government's strategy work?. Cmaj, 2005, 173, 1469-1470.	2.0	15
62	Multigenic Control of Drug Response and Regulatory Decision-Making in Pharmacogenomics: The Need for an Upper-Bound Estimate of Genetic Contributions. Current Pharmacogenomics and Personalized Medicine: the International Journal for Expert Reviews in Pharmacogenomics, 2005, 3, 53-71.	0.3	26
63	Techniques for knowledge discovery in existing biomedical databases Estimation of individual aging effects in cognition in relation to dementia. Journal of Clinical Epidemiology, 2003, 56, 116-123.	5.0	10
64	Actor-Network Theory: a tool to support ethical analysis of commercial genetic testing. New Genetics and Society, 2003, 22, 271-296.	1.2	85
65	Five-Year Follow-up of Cognitive Impairment With No Dementia. Archives of Neurology, 2003, 60, 577.	4.5	190
66	Patterns and Health Effects of Caring for People With Dementia: The Impact of Changing Cognitive and Residential Status. Gerontologist, The, 2002, 42, 643-652.	3.9	37
67	Frailty, fitness and late-life mortality in relation to chronological and biological age. BMC Geriatrics, 2002, 2, 1.	2.7	560
68	Harbinger of Hope or Commodity Fetishism: "Re-cognizing―Dementia in an Age of Therapeutic Agents. International Psychogeriatrics, 2001, 13, 131-134.	1.0	14
69	Qualitative Analysis of the Clinician Interview-Based Impression of Change (Plus): Methodological Issues and Implications for Clinical Research. International Psychogeriatrics, 2000, 12, 403-413.	1.0	36
70	Prevalence of Cognitive Impairment and Dementia as Defined by Neuropsychological Test Performance. Neuroepidemiology, 2000, 19, 121-129.	2.3	14
71	The Rate of Decline in Function in Alzheimer's Disease and Other Dementias. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 1999, 54, M65-M69.	3.6	39
72	Dynamics of Cognitive Aging: Distinguishing Functional Age and Disease from Chronologic Age in a Population. American Journal of Epidemiology, 1999, 150, 1045-1054.	3.4	30

#	Article	IF	CITATIONS
73	Factors Associated with Inconsistent Diagnosis of Dementia Between Physicians and Neuropsychologists. Journal of the American Geriatrics Society, 1999, 47, 1294-1299.	2.6	22
74	Modeling Decline in Alzheimer's Disease. International Psychogeriatrics, 1999, 11, 211-213.	1.0	2
75	Vector Diagnostics in Dementia Derived from Bayes' Theorem. American Journal of Epidemiology, 1997, 146, 665-671.	3.4	10
76	Prevalence and severity of cognitive impairment with and without dementia in an elderly population. Lancet, The, 1997, 349, 1793-1796.	13.7	893
77	Symptoms and Signs in Dementia Synergy and Antagonism. Dementia and Geriatric Cognitive Disorders, 1996, 7, 331-335.	1.5	12
78	Standardization of the Diagnosis of Dementia in the Canadian Study of Health and Aging. Neuroepidemiology, 1996, 15, 246-256.	2.3	126
79	An Algorithmic Approach to the Differential Diagnosis of Dementia. Dementia and Geriatric Cognitive Disorders, 1996, 7, 324-330.	1.5	5
80	Rendre évidentÂ: une approche symétrique de la réglementation des produits thérapeutiques. Sociologie Et Sociétés, 0, 42, 153-180.	0.1	5